Multaq Tablet, Film Coated
Product Images NDC 55154-8104

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Multaq (NDC 55154-8104). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5987bb71 D249 45fb B6fb C21799332de2 00

Multaq 400 mg film-coated tablets label displaying the proprietary name, generic name dronedarone, and dosage strength. The label states each tablet contains dronedarone hydrochloride equivalent to 400 mg dronedarone. It includes dispensing instructions to keep out of reach of children and a quantity of approximately 1260 tablets. The labeler is Cardinal Health 107, LLC with a barcode and distribution information.*

FDA Label Image

Chemical Structure (Multaq 01)

Chemical structure diagram of dronedarone, the active ingredient in Multaq 400 mg oral film-coated tablets. The diagram illustrates the molecular arrangement and functional groups present in dronedarone hydrochloride.*

FDA Label Image

Figure 1 (Multaq 02)

A forest plot chart illustrating drug-drug interactions with Dronedarone, showing mean ratio and 90% confidence intervals for various interacting drugs and grapefruit juice. The x-axis measures change relative to dronedarone alone, highlighting pharmacokinetic parameters Cmax and AUC, alongside recommendations like contraindications or dose adjustments.*

FDA Label Image

Figure 2 (Multaq 03)

A chart showing the mean ratio and 90% confidence interval for drug interactions with Multaq (dronedarone) 400 mg tablets. It plots change relative to interacting drugs alone, with red dots for Cmax and green triangles for AUC, comparing various interacting drugs and recommendations for dose adjustments or monitoring.*

FDA Label Image

Figure 1 (Multaq 04)

A line graph depicting cumulative incidence over a 30-month period comparing placebo and dronedarone groups. The x-axis represents months from 0 to 30, and the y-axis shows cumulative incidence ranging from 0.0 to 0.5. Two lines are shown: one solid line for placebo and a dotted line for dronedarone. Below the graph, numbers at risk for each group are listed at intervals, illustrating the declining sample size over time.*

FDA Label Image

Figure 2 (Multaq 05)

A forest plot chart presenting relative risk (RR) with 95% confidence intervals and p-values for various patient characteristics comparing Dronedarone and placebo efficacy. It includes age groups, gender, presence of atrial fibrillation/flutter, structural heart disease, NYHA class, left ventricular ejection fraction, beta-blocker usage, ACE inhibitors or ARBs, digitalis, and calcium antagonists.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.